Table S4.

Summary of probabilistic sensitivity analysis inputs and distributions

Variable	Value (95% CI)	Distribution	Source
Event rates for clopidogrel (1-year decision tree)
Dead any cause	0.0545 (0.05–0.059)	Lognormal	Based on the raw data from the PLATO study
Nonfatal MI	0.0522 (0.0477–0.0567)	Lognormal
Nonfatal stroke	0.008 (0.0062–0.0097)	Lognormal
Hazard ratios for ticagrelor versus clopidogrel (1-year decision tree)
Dead any cause	0.78 (0.69–0.89)	Lognormal	Based on the PLATO study
Nonfatal MI	0.86 (0.76–0.98)	Lognormal
Nonfatal stroke	1.09 (0.80–1.49)	Lognormal
Event rates (Markov model)
Subsequent events (MI, stroke, and vascular death)	Various	Normal	Coefficients for the risk equations from Karnon et al8 were varied around their respective SE
Utility values (decision tree and Markov model)
No further event	0.875 (0.871–0.879)	Beta	95% confidence intervals based on PLATO study
New MI	0.8120 (0.792–0.832)	Beta
New stroke	0.7360 (0.662–0.810)	Beta
Dead any cause	0.2490 (0.222–0.726)	Beta
Resource costs (decision tree)
No further event (ticagrelor)	$21,911	Gamma	Based on 95% confidence intervals of individual resource use from the PLATO study
New MI (ticagrelor)	$46,024	Gamma
New stroke (ticagrelor)	$51,351	Gamma
Dead any cause (ticagrelor)	$34,387	Gamma
No further event (clopidogrel)	$21,849	Gamma
New MI (clopidogrel)	$45,298	Gamma
New stroke (clopidogrel)	$58,769	Gamma
Dead any cause (clopidogrel)	$44,391	Gamma
Resource costs (Markov model)
New MI	$10,824	Gamma	As no standard error was reported in the original study, we assumed an SE equal to the mean
Post-MI/no event	$3,112	Gamma
New stroke	$20,823	Gamma
Post-stroke	$4,336	Gamma

Note: All values are in Canadian dollars.

Abbreviations: CI, confidence interval; MI, myocardial infarction; SE, standard error; PLATO, Platelet Inhibition and Patient Outcomes.